Hims & Hers said the U.S. FDA's decision that the shortage of Novo Nordisk's weight-loss and diabetes drugs had been resolved ...
Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended ...
Shares of Hims & Hers Health fell, dragged down by expectations that the telehealth-consultation platform will have to stop selling its weight-loss treatments, which boosted results in the fourth ...
Hims & Hers plans to launch a generic version of liraglutide, but its efficacy is significantly lower than semaglutide. See ...
Shares of Hims & Hers Health (HIMS) sank in after-hours trading after the healthcare company reported earnings for its fourth quarter of ...
Revenue excluding its GLP-1 offering increased 43% to $1.2 billion in 2024 from a year earlier, said Chief Financial Officer Yemi Okupe. Including sales of its weight-loss treatments, revenue surged ...
Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...
Hims & Hers Health (NYSE:HIMS) is set to report its earnings on Monday, Feb 24 after market close. HIMS stock plunged over 25 ...
The U.S. FDA has officially declared that Novo Nordisk’s (NVO) popular diabetes and weight loss therapies, Ozempic and Wegovy ...
Hims & Hers Health beat fourth-quarter estimates and guided for better-than-expected revenue in the first quarter and 2025. The telehealth provider logged earnings of 11 cents a share on revenue of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback